Abstract
Background: Polycystic ovary syndrome (PCOS) is a leading cause of anovulatory infertility. Letrozole is widely used for ovulation induction, while metformin is recommended for insulin resistance in PCOS. However, comparative evidence on short- versus extended-course letrozole combined with metformin remains limited. Methods & Materials: This quasi-experimental study included 100 infertile women with PCOS at Dhaka Medical College Hospital, aged 18-35 years with BMI 25-29.9 kg/m². All received metformin (1500 mg/day) for 3 months, followed by either extended-course letrozole (2.5 mg twice daily, days 2-11) or short-course letrozole (5 mg twice daily, days 2-6). Follicular development was assessed by transvaginal sonography, with ovulation confirmed by mid-luteal serum progesterone (≥3 ng/mL). Outcomes included follicular response, endometrial thickness, ovulation, and biochemical pregnancy rates over three cycles. Results: The mean age was 25.9 ± 4.4 years, with BMI 25-29.9 kg/m², and baseline characteristics and hormone profiles were comparable between groups. After three cycles, Group A showed significantly higher mean follicle number (2.36 ± 1.03 vs. 1.87 ± 1.09; p = 0.024) and follicle size (18.05 ± 1.82 vs. 17.62 ± 1.91 mm; p = 0.041) in the third cycle. Overall, follicle number was also higher in Group A (1.87 ± 1.18 vs. 1.66 ± 1.16; p = 0.048), while differences in follicle size and endometrial thickness were not significant. Ovulation (82% vs. 71%) and cumulative biochemical pregnancy rates (24% vs. 18%) were higher in Group A, although not significantly. Side effects were minimal in both groups. Conclusion: Extended-course letrozole with metformin improved follicular development and ovulation compared with the short course, with a non-significant trend toward higher biochemical pregnancy rates.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 The Insight




PDF